ATNM
AMEXActinium Pharmaceuticals Inc. (Delaware)
SectorHealth CareIndustryBiotechnology: Pharmaceutical Preparations
News · 26 weeks34+11%
2026-04-192026-10-11
Mix2290d
- Insider10(45%)
- SEC Filings5(23%)
- Other5(23%)
- Leadership2(9%)
Latest news
25 items- INSIDERSEC Form 4 filed by Actinium Pharmaceuticals Inc. (Delaware)4 - Actinium Pharmaceuticals, Inc. (0001388320) (Issuer)
- INSIDERSEC Form 3 filed by Actinium Pharmaceuticals Inc. (Delaware)3 - Actinium Pharmaceuticals, Inc. (0001388320) (Issuer)
- PRActinium Pharmaceuticals Announces Inducement Grants to New EmployeesNEW YORK, Oct. 16, 2026 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE:ATNM) ("Actinium" or the "Company"), a pioneer in the development of targeted radiotherapies, today announced inducement equity awards to Matt David, M.D., the Company's newly appointed Chief Financial Officer, and Sean Maenpaa, the Company's newly appointed Senior Vice President, Business Development. In connection with Dr. David's appointment, on October 14, 2026 the Company granted Dr. David a non-qualified stock option to purchase 250,000 shares of the Company's common stock at an exercise price of $0.97 per share, equal to the closing price of Act
- PRActinium Pharmaceuticals Announces Oral and Poster Presentations at EANM 2026 Highlighting Broad Antitumor Activity of ATNM-400 Across Lung, Colorectal and Ovarian Cancer ModelsOral presentation to highlight ATNM-400 antitumor activity across KRAS- and ALK-driven NSCLC models, building on earlier EGFR-mutant findings and supporting mutation-agnostic developmentColorectal cancer data demonstrate ATNM-400's potential to enhance responses to standard-of-care therapiesOvarian cancer data demonstrate the durable antitumor activity of ATNM-400, including in treatment-resistant modelsCollectively, the findings support the broad potential of ATNM-400 as a differentiated targeted radiotherapy across multiple large solid tumor indications, both as monotherapy and in combination with existing treatmentsNEW YORK, Oct. 16, 2026 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NY
- SECSEC Form DEF 14A filed by Actinium Pharmaceuticals Inc. (Delaware)DEF 14A - Actinium Pharmaceuticals, Inc. (0001388320) (Filer)
- PRActinium Pharmaceuticals Appoints Radiopharmaceutical Industry Veteran Sean Maenpaa as Senior Vice President, Business Development– Brings more than 20 years of oncology business development and commercial leadership, including senior roles across the radiopharmaceutical sector at Bayer, Clovis Oncology, Telix Pharmaceuticals and BWXT Medical– Will lead partnering, licensing and strategic transactions across Actinium's targeted radiotherapy pipelineNEW YORK, Oct. 16, 2026 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE:ATNM) ("Actinium" or the "Company"), a pioneer in the development of targeted radiotherapies, today announced the appointment of Sean Maenpaa as Senior Vice President, Business Development, effective October 12, 2026. Mr. Maenpaa will lead the Company's business development activities, including out
- SECSEC Form 8-K filed by Actinium Pharmaceuticals Inc. (Delaware)8-K - Actinium Pharmaceuticals, Inc. (0001388320) (Filer)
- PRActinium Pharmaceuticals Announces Oral Presentation at EANM 2026 Highlighting First-in-Human Phase 1 Study of ATNM-400, a Non-PSMA Targeting Radiotherapy, in Prostate CancerEarly clinical data from the Phase 1 theranostic trial support the advancement of ATNM-400 as a non-PSMA targeted alpha therapy for metastatic castration-resistant prostate cancer (mCRPC)Evaluation of Zirconium-89-labeled ATNM-400 to assess safety, biodistribution, and dosimetry to inform the development of Actinium-225-labeled ATNM-400 as a targeted radiotherapyATNM-400 is a first-in-class, non-PSMA targeted radiotherapy being developed to address a broad mCRPC patient population, including PSMA-low and PSMA-negative disease and patients who do not respond to or progress following PSMA-directed therapiesNEW YORK, Oct. 15, 2026 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE:ATNM) (Acti
- PRActinium Pharmaceuticals Strengthens Leadership Team with Appointment of Matt David, M.D. as Chief Financial OfficerNEW YORK, Oct. 15, 2026 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE:ATNM) ("Actinium" or the "Company"), a pioneer in the development of targeted radiotherapies, today announced the appointment of Matt David, M.D., as Chief Financial Officer. Dr. David will lead the Company's finance, accounting, capital markets and investor relations functions and will also serve as the Company's principal financial officer.Dr. David brings more than two decades of experience across biopharmaceutical operating leadership, healthcare investment banking and equity research. He joins Actinium from CorMedix Inc. (NASDAQ:CRMD), where he most recently served as Executive Vice President and Chief Business
- SECSEC Form S-8 filed by Actinium Pharmaceuticals Inc. (Delaware)S-8 - Actinium Pharmaceuticals, Inc. (0001388320) (Filer)
- INSIDERNew insider Kamal Adeela claimed ownership of 213,648 shares (SEC Form 3)3 - Actinium Pharmaceuticals, Inc. (0001388320) (Issuer)
- INSIDERNew insider Heeger Steffen Wilhem claimed ownership of 153,868 shares (SEC Form 3)3 - Actinium Pharmaceuticals, Inc. (0001388320) (Issuer)
- INSIDERDirector Nicholson, C. David was granted 62,800 shares, increasing direct ownership by 12,560% to 63,300 units (SEC Form 4)4 - Actinium Pharmaceuticals, Inc. (0001388320) (Issuer)
- INSIDERDirector Chell Jeffrey W. was granted 61,600 shares (SEC Form 4)4 - Actinium Pharmaceuticals, Inc. (0001388320) (Issuer)
- INSIDERDirector Steinhart Richard I was granted 62,800 shares, increasing direct ownership by 19,873% to 63,116 units (SEC Form 4)4 - Actinium Pharmaceuticals, Inc. (0001388320) (Issuer)
- INSIDERChief Executive Officer Seth Sandesh was granted 1,780,874 shares, increasing direct ownership by 965% to 1,965,355 units (SEC Form 4)4 - Actinium Pharmaceuticals, Inc. (0001388320) (Issuer)
- INSIDERDirector Almenoff June Sherie was granted 18,000 shares (SEC Form 4)4 - Actinium Pharmaceuticals, Inc. (0001388320) (Issuer)
- INSIDERDirector Shetty Ajit was granted 61,600 shares, increasing direct ownership by 8,137% to 62,357 units (SEC Form 4)4 - Actinium Pharmaceuticals, Inc. (0001388320) (Issuer)
- PRActinium Pharmaceuticals, Inc. to Present at the H.C. Wainwright 28th Annual Global Investment ConferenceNEW YORK, Sept. 4, 2026 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE:ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced that Sandesh Seth, Chairman and Chief Executive Officer, will present at the H.C. Wainwright 28th Annual Global Investment Conference, being held September 14-16, 2026, in New York, NY. Company management will also be available for one-on-one meetings with investors. Conference DetailsEvent: H.C. Wainwright 28th Annual Global Investment ConferencePresentation Date and Time: Monday, September 14, 2026, 3:00 – 3:30 p.m. ETLocation: New York, NYRegist
- PRActinium Pharmaceuticals Announces Actimab-A Intellectual Property and Manufacturing Advances and Provides NYSE American Listing UpdateNEW YORK, Aug. 14, 2026 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE:ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced advances across its Actimab-A program, including recently acquired patents adding to a broad suite of IP, and expansion of the Company's manufacturing capacity, as the program approaches clinical milestones from the fourth quarter of 2026 and into 2027. The Company also provided an update on the status of its NYSE American listing. Actiniums holds a broad IP portfolio covering the manufacture of Actimab-A, as well as its use alone and in combinatio
- SECActinium Pharmaceuticals Inc. (Delaware) filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Actinium Pharmaceuticals, Inc. (0001388320) (Filer)
- SECSEC Form 10-Q filed by Actinium Pharmaceuticals Inc. (Delaware)10-Q - Actinium Pharmaceuticals, Inc. (0001388320) (Filer)
- SECActinium Pharmaceuticals Inc. (Delaware) filed SEC Form 8-K: Other Events8-K - Actinium Pharmaceuticals, Inc. (0001388320) (Filer)
- PRActinium Presents New ATNM-400 Data in KRAS and EGFR Mutant Models at SNMMI 2026 Supporting a Mutation-Agnostic Opportunity In Non-Small Cell Lung CancerNew KRAS-mutant data show ATNM-400 outperformed standard-of-care inhibitors sotorasib and adagrasib as a monotherapy. Treatment with these agents increased expression of the ATNM-400 target greater than 3.5x and enhanced their effect in combination Additional data in the EGFR-mutant setting demonstrated powerful synergy with osimertinib due to enhanced target expression in treated animals resulting in complete tumor regression in the combination arm The data with EGFR and KRAS mutations which account for approximately 40-50 percent of all NSCLC cases provide compelling evidence of the potential of ATNM-400 as a monotherapy or in combination with inhibitory agents against these mutations ATNM
- PRActinium Pharmaceuticals Oral Presentation at SNMMI 2026 Highlights ATNM-400 Overcoming Resistance to All Three Approved Androgen Receptor Inhibitors and Offers Flexible, Well-Tolerated Dosing in Prostate Cancer ModelsNew data demonstrated ATNM-400 remains potently active in prostate cancer cells and tumors resistant to all three approved androgen receptor inhibitors (ARPIs) -enzalutamide (Xtandi®), apalutamide (Erleada®), and darolutamide (Nubeqa®)- directly targeting the point of failure for a high proportion of mCRPC patients ATNM-400 substantially outperformed apalutamide and darolutamide in an ARPI-resistant tumor model, and in combination with either ARPI it showed durable complete responses, supporting both monotherapy and combination strategies in refractory disease similar to prior data with enzalutamide ATNM-400 delivered superior tumor control as a single bolus or repeat dose with a consistent
ATNM FAQ
6 questionsWhat does Actinium Pharmaceuticals Inc. (Delaware) do?
Actinium Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for BMT conditioning; and a Phase I study with a CD19 CAR T-cell therapy with memorial sloan kettering cancer center. The company is also developing a multi-disease, multi-target pipeline of...Where does ATNM stock trade?
Actinium Pharmaceuticals Inc. (Delaware) (ATNM) is listed on AMEX.What sector and industry is ATNM in?
Actinium Pharmaceuticals Inc. (Delaware) operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about ATNM?
Actinium Pharmaceuticals Inc. (Delaware) has had 7 recent analyst actions on file. The most recent action was from B. Riley Securities: Neutral with a $200.00 price target on 2024-08-07.What companies are similar to ATNM?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare ATNM side-by-side with any of them on Quantisnow.How can I track ATNM on Quantisnow?
Quantisnow aggregates Actinium Pharmaceuticals Inc. (Delaware)'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ATNM to receive live email and push alerts on every new disclosure.